Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications

References

• Christensen DD. Alzheimer’s disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr.12(2), 113–116, 119–123 (2007).
   PubMedGoogle Scholar
• Wimo A. Clinical and economic outcomes – friend or foe? Int. Psychogeriatr.19(3), 497–507 (2007).
   Google Scholar
• Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med.256(3), 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med.256(3), 240–246 (2004).
   PubMed Web of Science ®Google Scholar
• Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology64(5), 834–841 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg SD, Che S, Counts SE, Mufson EJ. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. J. Neurochem.96(5), 1401–1408 (2006).
   Google Scholar
• Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J. Neurochem.97(2), 475–487 (2006).
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Schmitt FA, Kryscio RJ et al. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol.63(1), 38–46 (2006).
   PubMed Web of Science ®Google Scholar
• Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol.58(3), 397–405 (2001).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science302(5646), 830–834 (2003).
   PubMed Web of Science ®Google Scholar
• Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol.68(3), 209–245 (2002).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE. Basocortical cholinotrophic dysfunction during the early stages of Alzheimer’s disease. In: Alzheimer’s Disease and Related Disorders: Clinical and Basic Research Advances. Iqbal K, Winblad B (Eds). Alzheimer’s Association, Chicago, IL, USA 204–210 (2004).
   Google Scholar
• Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat.26(4), 233–242 (2003).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res.4(4), 340–350 (2007).
   PubMed Web of Science ®Google Scholar
• Counts SE, Perez SE, Mufson EJ. Galanin – 25 years with a multitalented neuropeptide: galanin in Alzheimer’s disease: neuroinhibitory or neuroprotective? Cell. Mol. Life Sci.65(12), 1842–1853 (2008).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Harbaugh RE, Schmitt FA et al. Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol.32(5), 625–632 (1992).
   PubMed Web of Science ®Google Scholar
• Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol.163(2), 495–529 (2000).
   PubMed Web of Science ®Google Scholar
• Davis KL, Mohs RC, Marin D et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA281(15), 1401–1406 (1999).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Ikonomovic MD, Styren SD et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol.51(2), 145–155 (2002).
   PubMed Web of Science ®Google Scholar
• Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol.64(4), 263–272 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez-Isla T, Price JL, McKeel DW Jr. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci.16(14), 4491–4500 (1996).
   PubMed Web of Science ®Google Scholar
• Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science225(4667), 1168–1170 (1984).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Chu Y, Stebbins GT et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol.49(2), 202–213 (2001).
   PubMed Web of Science ®Google Scholar
• Hyman BT, Kromer LJ, Van Hoesen GW. Reinnervation of the hippocampal perforant pathway zone in Alzheimer’s disease. Ann. Neurol.21(3), 259–267 (1987).
   PubMed Web of Science ®Google Scholar
• Cotman CW, Matthews DA, Taylor D, Lynch G. Synaptic rearrangement in the dentate gyrus: histochemical evidence of adjustments after lesions in immature and adult rats. Proc. Natl Acad. Sci. USA70(12), 3473–3477 (1973).
   PubMed Web of Science ®Google Scholar
• Savaskan NE, Nitsch R. Molecules involved in reactive sprouting in the hippocampus. Rev. Neurosci.12(3), 195–215 (2001).
   Google Scholar
• Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Exp. Neurol.105(3), 221–232 (1989).
   PubMed Web of Science ®Google Scholar
• Bierer LM, Haroutunian V, Gabriel S et al. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J. Neurochem.64(2), 749–760 (1995).
   PubMed Web of Science ®Google Scholar
• Rinne JO, Kaasinen V, Jarvenpaa T et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry74(1), 113–115 (2003).
   PubMed Web of Science ®Google Scholar
• Shinotoh H, Namba H, Fukushi K et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer’s disease: a positron emission tomography study. Ann. Neurol.48(2), 194–200 (2000).
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Wishart HA, Rabin LA et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain127(Pt 7), 1574–1583 (2004).
   PubMed Web of Science ®Google Scholar
• Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann. Neurol.34(3), 373–384 (1993).
   PubMed Web of Science ®Google Scholar
• Holmes C, Ballard C, Lehmann D et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry76(5), 640–643 (2005).
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem. Res.28(3–4), 515–522 (2003).
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol.4(4), 273–277 (1978).
   PubMed Web of Science ®Google Scholar
• Gauthier S. Advances in the pharmacotherapy of Alzheimer’s disease. CMAJ166(5), 616–623 (2002).
   Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet2(8000), 1403 (1976).
   PubMed Web of Science ®Google Scholar
• Saper CB, German DC, White CL III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer’s type: possible role in cell loss. Neurology35(8), 1089–1095 (1985).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol.10(2), 122–126 (1981).
   PubMed Web of Science ®Google Scholar
• Gilmor ML, Erickson JD, Varoqui H et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer’s disease. J. Comp. Neurol.411(4), 693–704 (1999).
   PubMed Web of Science ®Google Scholar
• Ruberg M, Mayo W, Brice A et al. Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer’s disease, Parkinson’s disease, and rats with basal forebrain lesions. Neuroscience35(2), 327–333 (1990).
   Google Scholar
• Eiden LE. The cholinergic gene locus. J. Neurochem.70(6), 2227–2240 (1998).
   Google Scholar
• Gilmor ML, Counts SE, Wiley RG, Levey AI. Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal pathway lesions. J. Neurochem.71(6), 2411–2420 (1998).
   Google Scholar
• Ginsberg SD, Martin LJ. Ultrastructural analysis of the progression of neurodegeneration in the septum following fimbria–fornix transection. Neuroscience86, 1259–1272 (1998).
   Google Scholar
• Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci.24, 1217–1281 (2001).
   PubMed Web of Science ®Google Scholar
• Rinne JO, Paljarvi L, Rinne UK. Neuronal size and density in the nucleus basalis of Meynert in Alzheimer’s disease. J. Neurol. Sci.79(1–2), 67–76 (1987).
   PubMed Web of Science ®Google Scholar
• Pearson RC, Sofroniew MV, Cuello AC et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer’s type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res.289(1–2), 375–379 (1983).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Kordower JH. Nerve growth factor in Alzheimer’s disease. In: Cerebral Cortex. Peter AA, Morrison JH (Eds). Kluwer Academic/Plenum Press, NY, USA 681–731 (1999).
   Google Scholar
• Edwards RH, Selby MJ, Garcia PD, Rutter WJ. Processing of the native nerve growth factor precursor to form biologically active nerve growth factor. J. Biol. Chem.263(14), 6810–6815 (1988).
   Google Scholar
• Kaplan DR, Miller FD. Neurobiology: a move to sort life from death. Nature427(6977), 798–799 (2004).
   PubMed Web of Science ®Google Scholar
• Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog. Neurobiol.67(3), 203–233 (2002).
   PubMed Web of Science ®Google Scholar
• Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV. Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J. Neurosci.18(9), 3273–3281 (1998).
   PubMed Web of Science ®Google Scholar
• Frade JM. Unscheduled re-entry into the cell cycle induced by NGF precedes cell death in nascent retinal neurones. J. Cell Sci.113(Pt 7), 1139–1148 (2000).
   PubMed Web of Science ®Google Scholar
• Bamji SX, Majdan M, Pozniak CD et al. The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. J. Cell Biol.140(4), 911–923 (1998).
   PubMed Web of Science ®Google Scholar
• Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science294(5548), 1945–1948 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman WJ. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J. Neurosci.20(17), 6340–6346 (2000).
   PubMed Web of Science ®Google Scholar
• Nykjaer A, Lee R, Teng KK et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature427(6977), 843–848 (2004).
   PubMed Web of Science ®Google Scholar
• Mamidipudi V, Wooten MW. Dual role for p75(NTR) signaling in survival and cell death: can intracellular mediators provide an explanation? J. Neurosci. Res.68(4), 373–384 (2002).
   PubMed Web of Science ®Google Scholar
• Teng KK, Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell. Mol. Life Sci.61(1), 35–48 (2004).
   PubMed Web of Science ®Google Scholar
• Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer’s disease. Mol. Cell. Neurosci.18(2), 210–220 (2001).
   PubMed Web of Science ®Google Scholar
• Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer’s disease. J. Neuropathol. Exp. Neurol.63(6), 641–649 (2004).
   PubMed Web of Science ®Google Scholar
• Fahnestock M, Yu G, Michalski B et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J. Neurochem.89(3), 581–592 (2004).
   PubMedGoogle Scholar
• Rattenholl A, Lilie H, Grossmann A et al. The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur. J. Biochem.268(11), 3296–3303 (2001).
   Google Scholar
• Counts SE, Nadeem M, Wuu J et al. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann. Neurol.56(4), 520–531 (2004).
   PubMed Web of Science ®Google Scholar
• Blasko I, Lederer W, Oberbauer H et al. Measurement of thirteen biological markers in csf of patients with Alzheimer’s disease and other dementias. Dement Geriatr. Cogn. Disord.21(1), 9–15 (2005).
   Google Scholar
• Costantini C, Weindruch R, Della Valle G, Puglielli L. A TrkA-to-p75NTR molecular switch activates amyloid β-peptide generation during aging. Biochem. J.391(Pt 1), 59–67 (2005).
   PubMed Web of Science ®Google Scholar
• Paiardini A, Caputo V. Insights into the interaction of sortilin with proneurotrophins: a computational approach. Neuropeptides42(2), 205–214 (2008).
   Google Scholar
• Nyborg AC, Ladd TB, Zwizinski CW, Lah JJ, Golde TE. Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates. Mol. Neurodegener.1, 3 (2006).
   Google Scholar
• Jansen P, Giehl K, Nyengaard JR et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat. Neurosci.10(11), 1449–1457 (2007).
   PubMed Web of Science ®Google Scholar
• Bronfman FC, Fainzilber M. Multi-tasking by the p75 neurotrophin receptor: sortilin things out? EMBO Rep.5(9), 867–871 (2004).
   Google Scholar
• Teng HK, Teng KK, Lee R et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci.25(22), 5455–5463 (2005).
   PubMed Web of Science ®Google Scholar
• Bruno MA, Clarke PB, Seltzer A et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J. Neurosci.24(37), 8009–8018 (2004).
   PubMedGoogle Scholar
• Longo FM, Yang T, Knowles JK et al. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer’s disease mechanisms. Curr. Alzheimer Res.4(5), 503–506 (2007).
   PubMed Web of Science ®Google Scholar
• Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. USA103(17), 6735–6740 (2006).
   PubMed Web of Science ®Google Scholar
• Bruno MA, Counts SE, Mufson EJ, Cuello AC. Increased MMP-9 cortical level and activity in subjects with mild cognitive impairment. Presented at: Society for Neuroscience Annual Meeting. San Diego, CA, USA, 3–7 November 2007.
   Google Scholar
• Lorenzl S, Albers DS, LeWitt PA et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci.207(1–2), 71–76 (2003).
   PubMedGoogle Scholar
• Lorenzl S, Buerger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int. Psychogeriatr.20(1), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Zucker S, Hymowitz M, Conner C et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. NY Acad. Sci.878, 212–227 (1999).
   Google Scholar
• Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann. NY Acad. Sci.766, 442–458 (1995).
   PubMed Web of Science ®Google Scholar
• Cunningham ME, Greene LA. A function–structure model for NGF-activated TRK. EMBO J.17(24), 7282–7293 (1998).
   Google Scholar
• McInnes C, Sykes BD. Growth factor receptors: structure, mechanism, and drug discovery. Biopolymers43(5), 339–366 (1997).
   PubMed Web of Science ®Google Scholar
• Bonni A, Brunet A, West AE et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science286(5443), 1358–1362 (1999).
   PubMed Web of Science ®Google Scholar
• Descamps S, Toillon RA, Adriaenssens E et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J. Biol. Chem.276(21), 17864–17870 (2001).
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol.10(3), 381–391 (2000).
   PubMed Web of Science ®Google Scholar
• Grewal SS, York RD, Stork PJ. Extracellular-signal-regulated kinase signalling in neurons. Curr. Opin. Neurobiol.9(5), 544–553 (1999).
   PubMed Web of Science ®Google Scholar
• Gomez N, Cohen P. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases. Nature353(6340), 170–173 (1991).
   PubMed Web of Science ®Google Scholar
• Howe LR, Leevers SJ, Gomez N et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell71(2), 335–342 (1992).
   PubMed Web of Science ®Google Scholar
• Kamata H, Tanaka C, Yagisawa H et al. Suppression of nerve growth factor-induced neuronal differentiation of PC12 cells. N-acetylcysteine uncouples the signal transduction from ras to the mitogen-activated protein kinase cascade. J. Biol. Chem.271(51), 33018–33025 (1996).
   PubMed Web of Science ®Google Scholar
• Kimpinski K, Mearow K. Neurite growth promotion by nerve growth factor and insulin-like growth factor-1 in cultured adult sensory neurons: role of phosphoinositide 3-kinase and mitogen activated protein kinase. J. Neurosci. Res.63(6), 486–499 (2001).
   PubMedGoogle Scholar
• Andjelkovic M, Suidan HS, Meier R et al. Nerve growth factor promotes activation of the α, β and γ isoforms of protein kinase B in PC12 pheochromocytoma cells. Eur. J. Biochem.251(1–2), 195–200 (1998).
   Google Scholar
• Ashcroft M, Stephens RM, Hallberg B, Downward J, Kaplan DR. The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth. Oncogene18(32), 4586–4597 (1999).
   PubMed Web of Science ®Google Scholar
• Vaillant AR, Mazzoni I, Tudan C et al. Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J. Cell Biol.146(5), 955–966 (1999).
   PubMedGoogle Scholar
• Klesse LJ, Parada LF. Trks: signal transduction and intracellular pathways. Microsc. Res. Tech.45(4–5), 210–216 (1999).
   PubMedGoogle Scholar
• Stephens RM, Loeb DM, Copeland TD et al. Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ 1 to mediate NGF responses. Neuron12(3), 691–705 (1994).
   PubMed Web of Science ®Google Scholar
• Vetter ML, Martin-Zanca D, Parada LF, Bishop JM, Kaplan DR. Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-γ 1 by a kinase activity associated with the product of the trk protooncogene. Proc. Natl Acad. Sci. USA88(13), 5650–5654 (1991).
   PubMed Web of Science ®Google Scholar
• Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol.11(3), 272–280 (2001).
   PubMed Web of Science ®Google Scholar
• Lad SP, Neet KE, Mufson EJ. Nerve growth factor: structure, function and therapeutic implications for Alzheimer’s disease. Curr. Drug Target CNS Neurol. Disord.2(5), 315–334 (2003).
   PubMedGoogle Scholar
• Brann AB, Scott R, Neuberger Y et al. Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J. Neurosci.19(19), 8199–8206 (1999).
   PubMed Web of Science ®Google Scholar
• DeFreitas MF, McQuillen PS, Shatz CJ. A novel p75NTR signaling pathway promotes survival, not death, of immunopurified neocortical subplate neurons. J. Neurosci.21(14), 5121–5129 (2001).
   PubMedGoogle Scholar
• Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA. Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science265(5178), 1596–1599 (1994).
   PubMed Web of Science ®Google Scholar
• Barrett GL. The p75 neurotrophin receptor and neuronal apoptosis. Prog. Neurobiol.61(2), 205–229 (2000).
   PubMed Web of Science ®Google Scholar
• Brann AB, Tcherpakov M, Williams IM, Futerman AH, Fainzilber M. Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase. J. Biol. Chem.277(12), 9812–9818 (2002).
   Google Scholar
• Harrington AW, Kim JY, Yoon SO. Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis. J. Neurosci.22(1), 156–166 (2002).
   PubMed Web of Science ®Google Scholar
• Bhakar AL, Roux PP, Lachance C et al. The p75 neurotrophin receptor (p75NTR) alters tumor necrosis factor-mediated NF-κB activity under physiological conditions, but direct p75NTR-mediated NF-κB activation requires cell stress. J. Biol. Chem.274(30), 21443–21449 (1999).
   PubMed Web of Science ®Google Scholar
• Cosgaya JM, Shooter EM. Binding of nerve growth factor to its p75 receptor in stressed cells induces selective IκB-β degradation and NF-κB nuclear translocation. J. Neurochem.79(2), 391–399 (2001).
   Google Scholar
• Foehr ED, Lin X, O’Mahony A et al. NF-κB signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. J. Neurosci.20(20), 7556–7563 (2000).
   PubMed Web of Science ®Google Scholar
• Gentry JJ, Casaccia-Bonnefil P, Carter BD. Nerve growth factor activation of nuclear factor κB through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells. J. Biol. Chem.275(11), 7558–7565 (2000).
   Google Scholar
• Hamanoue M, Middleton G, Wyatt S et al. p75-mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol. Cell. Neurosci.14(1), 28–40 (1999).
   PubMed Web of Science ®Google Scholar
• Hughes AL, Messineo-Jones D, Lad SP, Neet KE. Distinction between differentiation, cell cycle, and apoptosis signals in PC12 cells by the nerve growth factor mutant delta9/13, which is selective for the p75 neurotrophin receptor. J. Neurosci. Res.63(1), 10–19 (2001).
   Google Scholar
• Roux PP, Bhakar AL, Kennedy TE, Barker PA. The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem.276(25), 23097–23104 (2001).
   Google Scholar
• Susen K, Heumann R, Blochl A. Nerve growth factor stimulates MAPK via the low affinity receptor p75(LNTR). FEBS Lett.463(3), 231–234 (1999).
   PubMedGoogle Scholar
• Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimer‘s disease. In: Neurobiology of Alzheimer’s Disease. Dawbarn D, Allen SJ (Eds). Oxford University Press, Oxford, UK 283–321 (2007).
   Google Scholar
• Tuszynski MH, Thal L, Pay M et al. A Phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med.11(5), 551–555 (2005).
   PubMed Web of Science ®Google Scholar
• Morse JK, Wiegand SJ, Anderson K et al. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J. Neurosci.13(10), 4146–4156 (1993).
   PubMed Web of Science ®Google Scholar
• Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol. Disord. Drug Targets7(1), 46–62 (2008).
   PubMed Web of Science ®Google Scholar
• Jang SW, Okada M, Sayeed I et al. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc. Natl Acad. Sci. USA104(41), 16329–16334 (2007).
   PubMed Web of Science ®Google Scholar
• Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog. Neurobiol.53(2), 199–237 (1997).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Jaffar S, Levey AI. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer’s disease: relationship with cholinergic and galaninergic perikarya. J. Comp. Neurol.392(3), 313–329 (1998).
   Google Scholar
• Counts SE, He B, Che S et al. α7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer’s disease. Arch. Neurol.64(12), 1771–1776 (2007).
   PubMedGoogle Scholar
• Chu LW, Ma ES, Lam KK, Chan MF, Lee DH. Increased α 7 nicotinic acetylcholine receptor protein levels in Alzheimer’s disease patients. Dement. Geriatr. Cogn. Disord.19(2–3), 106–112 (2005).
   Google Scholar
• Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res.66(1–2), 94–103 (1999).
   PubMedGoogle Scholar
• Teaktong T, Graham A, Court J et al. Alzheimer’s disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia41(2), 207–211 (2003).
   PubMed Web of Science ®Google Scholar
• Nagele RG, D’Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of β-amyloid(1–42) in neurons is facilitated by the α 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience110(2), 199–211 (2002).
   PubMed Web of Science ®Google Scholar
• Small DH, Maksel D, Kerr ML et al. The β-amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor. J. Neurochem.101(6), 1527–1538 (2007).
   Google Scholar
• Wang HY, Lee DH, D’Andrea MR et al. β-amyloid(1–42) binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer’s disease pathology. J. Biol. Chem.275(8), 5626–5632 (2000).
   PubMed Web of Science ®Google Scholar
• Counts SE, He B, Che S, Ginsberg SD, Mufson EJ. Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer’s disease. Neurodegener. Dis.5(3–4), 228–231 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease – the pivotal role of brain M1 receptors. Neurodegener. Dis.5(3–4), 237–240 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease – an update. Curr. Alzheimer Res.4(5), 577–580 (2007).
   PubMed Web of Science ®Google Scholar
• Fisher A, Brandeis R, Bar-Ner RH et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease. J. Mol. Neurosci.19(1–2), 145–153 (2002).
   Google Scholar
• Caccamo A, Oddo S, Billings LM et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron49(5), 671–682 (2006).
   PubMed Web of Science ®Google Scholar
• Ginsberg SD, Che S, Counts SE, Mufson EJ. Single cell gene expression profiling in Alzheimer’s disease. NeuroRx3(3), 302–318 (2006).
   Google Scholar
• Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol. Aging27(10), 1372–1384 (2005).
   Google Scholar
• Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol.30(4), 572–580 (1991).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE, Che S, Ginsberg SD. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Prog. Brain Res.158, 197–222 (2006).
   Google Scholar
• Mufson EJ, Counts SE, Ginsberg SD. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer’s disease. Neurochem. Res.27(10), 1035–1048 (2002).
   Google Scholar
• Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Ann. Neurol.48(1), 77–87 (2000).
   PubMed Web of Science ®Google Scholar
• Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci.22(8), 1942–1950 (2005).
   PubMed Web of Science ®Google Scholar
• Rahman A, Grundke-Iqbal I, Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem. Res.30(2), 277–287 (2005).
   Google Scholar
• Forman MS, Mufson EJ, Leurgans S et al. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology68(10), 757–763 (2007).
   Google Scholar
• Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. Neurol.55(6), 815–828 (2004).
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron3(4), 519–526 (1989).
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J.8(2), 393–399 (1989).
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Boom A, Leroy K, Brion JP. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer’s disease. FEBS Lett.576(1–2), 183–189 (2004).
   Google Scholar
• Hyman BT, Augustinack JC, Ingelsson M. Transcriptional and conformational changes of the tau molecule in Alzheimer’s disease. Biochim. Biophys. Acta1739(2–3), 150–157 (2005).
   Google Scholar
• Togo T, Akiyama H, Iseki E et al. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol.107(6), 504–508 (2004).
   Google Scholar
• Crawley JN. Galanin – 25 years with a multitalented neuropeptide: galanin impairs cognitive abilities in rodents: relevance to Alzheimer’s disease. Cell. Mol. Life Sci.65(12), 1836–1841 (2008).
   PubMed Web of Science ®Google Scholar
• Hobson SA, Bacon A, Elliot-Hunt CR et al. Galanin – 25 years with a multitalented neuropeptide: galanin acts as a trophic factor to the central and peripheral nervous systems. Cell. Mol. Life Sci.65(12), 1806–1812 (2008).
   Google Scholar
• Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J. Comp. Neurol.273(4), 543–557 (1988).
   PubMed Web of Science ®Google Scholar
• Counts SE, Perez SE, Ginsberg SD, De Lacalle S, Mufson EJ. Galanin in Alzheimer disease. Mol. Interv.3(3), 137–156 (2003).
   Google Scholar
• Mufson EJ, Cochran E, Benzing W, Kordower JH. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer’s disease and Down’s syndrome. Dementia4(5), 237–250 (1993).
   PubMedGoogle Scholar
• Counts SE, Chen EY, Che S et al. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.21(4), 205–214 (2006).
   PubMed Web of Science ®Google Scholar
• Jhamandas JH, Harris KH, MacTavish D, Jassar BS. Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer’s disease. J. Neurophysiol.87(2), 696–704 (2002).
   Google Scholar
• Ding X, MacTavish D, Kar S, Jhamandas JH. Galanin attenuates β-amyloid (Aβ) toxicity in rat cholinergic basal forebrain neurons. Neurobiol. Dis.21(2), 413–420 (2006).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE, Perez SE, Binder L. Galanin plasticity in the cholinergic basal forebrain in Alzheimer’s disease and transgenic mice. Neuropeptides39(3), 232–236 (2005).
   Google Scholar
• Trojanowski JQ, Lee VM. Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions: focusing on phosphatases. Faseb J.9(15), 1570–1576 (1995).
   PubMed Web of Science ®Google Scholar
• Liu HX, Brumovsky P, Schmidt R et al. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc. Natl. Acad. Sci. USA98(17), 9960–9964 (2001).
   PubMed Web of Science ®Google Scholar
• Mahoney SA, Hosking R, Farrant S et al. The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J. Neurosci.23(2), 416–421 (2003).
   PubMed Web of Science ®Google Scholar
• Planas B, Kolb PE, Raskind MA, Miller MA. Nerve growth factor induces galanin gene expression in the rat basal forebrain: implications for the treatment of cholinergic dysfunction. J. Comp. Neurol.379(4), 563–570 (1997).
   Google Scholar
• Ballard CG, Chalmers KA, Todd C et al. Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies. Neurology68(20), 1726–1729 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wisniewski S et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry72(3), 310–314 (2002).
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Charles HC, Doraiswamy PM et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am. J. Psychiatry160(11), 2003–2011 (2003).
   PubMed Web of Science ®Google Scholar
• Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol. Sci.26(2), 104–111 (2005).
   PubMed Web of Science ®Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis. Assoc. Disord.20(2 Suppl. 1), S12–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Perez CA et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron16(4), 881–891 (1996).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol.10(3), 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Burgos I, Cuello AC, Liberini P, Pioro E, Masliah E. NGF-mediated synaptic sprouting in the cerebral cortex of lesioned primate brain. Brain Res.692(1–2), 154–160 (1995).
   Google Scholar
• Charles V, Mufson EJ, Friden PM, Bartus RT, Kordower JH. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res.728(2), 193–203 (1996).
   PubMed Web of Science ®Google Scholar
• Hartikka J, Hefti F. Comparison of nerve growth factor’s effects on development of septum, striatum, and nucleus basalis cholinergic neurons. J. Neurosci. Res.21(2–4), 352–364 (1988).
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Nihonmatsu I, Tsukui H. Nerve growth factor promotes survival of cultured magnocellular cholinergic neurons from nucleus basalis of Meynert in postnatal rats. Neurosci. Lett.90(1–2), 63–68 (1988).
   Google Scholar
• Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci.6(8), 2155–2162 (1986).
   PubMed Web of Science ®Google Scholar
• Humpel C, Weis C. Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices. Implication in Alzheimer’s disease? J. Neural Transm. Suppl. (62), 253–263 (2002).
   Google Scholar
• Williams LR, Varon S, Peterson GM et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. USA83(23), 9231–9235 (1986).
   PubMed Web of Science ®Google Scholar
• Nabeshima T, Nitta A, Fuji K, Kameyama T, Hasegawa T. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. Gerontology40 (Suppl. 2), 46–56 (1994).
   Google Scholar
• Chu Y, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer’s disease. J. Comp. Neurol.437(3), 296–307 (2001).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Ma SY, Cochran EJ et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J. Comp. Neurol.427(1), 19–30 (2000).
   PubMedGoogle Scholar
• Mufson EJ, Ma SY, Dills J et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer’s disease. J. Comp. Neurol.443(2), 136–153 (2002).
   PubMed Web of Science ®Google Scholar
• Knusel B, Gao H. Neurotrophins and Alzheimer’s disease: beyond the cholinergic neurons. Life Sci.58(22), 2019–2027 (1996).
   Google Scholar
• Apfel SC. Neurotrophic factor therapy – prospects and problems. Clin. Chem. Lab. Med.39(4), 351–355 (2001).
   PubMed Web of Science ®Google Scholar
• Jonhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis. Assoc. Disord.14 (Suppl. 1), S31–S38 (2000).
   PubMedGoogle Scholar
• McArthur JC, Yiannoutsos C, Simpson DM et al. A Phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology54(5), 1080–1088 (2000).
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging14(5), 359–373 (1999).
   PubMed Web of Science ®Google Scholar
• Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol.50, 393–413 (2002).
   PubMed Web of Science ®Google Scholar
• Winkler J, Ramirez GA, Kuhn HG et al. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol.41(1), 82–93 (1997).
   PubMedGoogle Scholar
• Blesch A, Tuszynski M. Ex vivo gene therapy for Alzheimer’s disease and spinal cord injury. Clin. Neurosci.3(5), 268–274 (1995).
   Google Scholar
• Gage FH, Rosenberg MB, Tuszynski MH et al. Gene therapy in the CNS: intracerebral grafting of genetically modified cells. Prog. Brain Res.86, 205–217 (1990).
   Google Scholar
• Gage FH, Tuszynski MH, Chen KS, Armstrong D, Buzsaki G. Survival, growth and function of damaged cholinergic neurons. EXS57, 259–274 (1989).
   Google Scholar
• Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Brain Res.285(1), 45–52 (1983).
   Google Scholar
• Hefti F, Hartikka J, Knusel B. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol. Aging10(5), 515–533 (1989).
   PubMed Web of Science ®Google Scholar
• Higgins GA, Koh S, Chen KS, Gage FH. NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat. Neuron3(2), 247–256 (1989).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther.3(4), 305–314 (1996).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol.30(5), 625–636 (1991).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, U HS, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J. Neurosci.10(11), 3604–3614 (1990).
   PubMed Web of Science ®Google Scholar
• Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer’s disease. Neuroscience75(2), 373–387 (1996).
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet372(9634), 207–215 (2008).
   PubMed Web of Science ®Google Scholar
• Blesch A. Delivery of neurotrophic factors to neuronal targets: toward gene therapy in the CNS. Drug News Perspect.13(5), 269–280 (2000).
   Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4), 547–554 (2003).
   PubMed Web of Science ®Google Scholar